ARS Pharma reported third-quarter revenue of $37.7 million, including $33.4 million in U.S. NEPHE product revenue, while affirming a path to cash flow break-even by year-end 2027. ARS-2 interim data are expected in the first quarter of 2027.
SPRY · ARS Pharmaceuticals, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 48%
- Last earnings
- Nov 5, 2026
- Latest filing
- 10-Q · Nov 5
- Price history
- Dec 2020 to Nov 2026
Up next
Latest documents
ARS Pharmaceuticals reported nine-month 2026 revenue of $94.0 million, versus $56.2 million in 2025, and net loss of $158.5 million. neffy generated $77.1 million in U.S. net product revenue, while cash, cash equivalents and short-term investments totaled $138.4 million at September 30, 2026.
ARS Pharmaceuticals reported third-quarter revenue of $37.7 million, up from $32.5 million, while operating expenses fell to $71.9 million and net loss narrowed to $35.6 million from $51.2 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. NEPHE revenue, market share, prescriber reach and financial discipline improved. Risks include continued net losses, higher R&D spending, inventory-related revenue volatility, coverage gaps and delayed commercial benefits, alongside an ARS-2 interim data catalyst in the first quarter of 2027.
- + NEPHE U.S. net product revenue increased to $33.4 million from $31.3 million. new
- + Total U.S. NEPHE market share increased to 5% from 4% year over year. new
- + Field-targeted market share rose to approximately 9% from 6% year over year. new
- + Quarterly unique prescribers increased 49% to 19,605. new
- + Q3 SG&A fell to $43.5 million from $74.8 million. new
- + ARS-2 Phase 2b interim data are expected in the first quarter of 2027, with full data later in 2027 informing a potential Phase 3 program. new
- − The company remained unprofitable, with a Q3 net loss of $35.6 million. new
- − R&D expenses increased to $18.3 million from $2.8 million, primarily due to a one-time license payment. new
- − NEPHE share remained only 2% in non-targeted accounts. new
- − Net revenue growth lagged end-user demand because of inventory-related changes. new
- − Coverage gaps remain in the remaining Medicaid states and commercial plans. new
- − Benefits from the commercial reset were not expected to become increasingly visible until the first half of 2027. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and short-term investments | $138.4M | As of September 30, 2026 | — |
| Market share among field-targeted accounts | 9% | the third quarter of 2026 | — |
|
|
|||
| Net U.S. product revenue (neffy) | $33.4M | the third quarter of 2026 | +6.7% |
|
|
|||
| Prescriber base | 19,605 | the third quarter of 2026 | — |
| Total U.S. market share | 5% | the third quarter of 2026 | — |
| U.S. net product revenue | $33.41M | FY2026 Q3 | +6.8% |
|
|
|||
| Total U.S. epinephrine market share | 5% | Q2 2026 | — |
| Unique prescribers | 16,000 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SPRY
this stock
ARS Pharmaceuticals, Inc.
|
$337.78M | -71.2% | -5.5% | — | 18.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 5, 2026
- This year
- 15
ARS Pharmaceuticals reported nine-month 2026 revenue of $94.0 million, versus $56.2 million in 2025, and net loss of $158.5 million. neffy generated $77.1 million in U.S. net product revenue, while cash, cash equivalents and short-term investments totaled $138.4 million at September 30, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SPRY | -11.8% | -22.2% | -64.4% | -0.6% | -71.2% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -6.4% | -15.9% | -58.7% | +4.7% | -76.1% |